# US 8,772,278 B2 · Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,278 B2
- Document ID: US8772278B2
- Status: Granted
- Kind: B2
- Application number: 11/973,250
- Filed: 2007-10-05
- Published: 2008-06-19
- Granted: 2014-07-08
- Earliest claimed: 2006-10-06
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Applicants: Marcus Stark; Ulrike Sent; Ingo Lang
- Inventors: Marcus Stark; Ulrike Sent; Ingo Lang
- Web page: https://patentgrep.com/patent/US8772278B2

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of prophylaxis or treatment of systemic diseases in cats, wherein the method comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.

## Claims

### Claim 1

A method for the treatment of a systemic disease in a cat in need thereof, the method comprising once daily oral administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to said cat, wherein the systemic disease is chronic kidney disease, and the therapeutically effective amount of the sartan is about 3.0 mg/kg of body weight, wherein the angiotensin II receptor 1 (AT-1) antagonist is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, and a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method further comprises administration of at least one other drug to such cat in need of such a treatment.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the other drug is selected from the group consisting of Ca-channel blockers, beta-blockers, cardiotonic-Ca-sensitising agents, selective If-current inhibitors, ACE inhibitors, and anti-obesity drugs.

### Claim 4

A method for the treatment of a systemic disease in a cat in need thereof, the method comprising once daily oral administration of a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist (sartan) selected from the group consisting of irbesartan, losartan, and telmisartan to said cat, wherein the systemic disease is chronic kidney disease, and the therapeutically effective amount of the sartan is about 3.0 mg/kg of body weight.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the chronic kidney disease is tubulointerstitial nephritis.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the sartan is telmisartan.